Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives

References

• OgdieAWeissPThe epidemiology of psoriatic arthritisRheum Dis Clin North Am201541454556826476218
   PubMed Web of Science ®Google Scholar
• MollJWrightVPsoriatic arthritisSemin Arthritis Rheum19733155784581554
   PubMedGoogle Scholar
• TaylorWGladmanDHelliwellPCASPAR Study GroupClassification criteria for psoriatic arthritis development of new criteria from a large international studyArthritis Rheum20065482665267316871531
   PubMed Web of Science ®Google Scholar
• AshZGaujoux-VialaCGossecLA systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritisAnn Rheum Dis201271331932621803753
   PubMed Web of Science ®Google Scholar
• GottliebAKormanNJGordonKBGuidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsJ Am Acad Dermatol200858585186418423261
   PubMed Web of Science ®Google Scholar
• KingsleyGHKowalczykATaylorHA randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology (Oxford)20125181368137722344575
   PubMed Web of Science ®Google Scholar
• CoatesLCKavanaughAMeasePJGroup for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritisArthritis Rheumatol20166851060107126749174
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSGaujoux-VialaCEuropean League against RheumatismEuropean league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesAnn Rheum Dis201271141221953336
   PubMed Web of Science ®Google Scholar
• FagerliKMLieEVan Der HeijdeDSwitching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD studyAnn Rheum Dis201372111840184423562987
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232
   PubMed Web of Science ®Google Scholar
• McInnesIBMeasePJKirkhamBFUTURE 2 Study GroupSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538699991137114626135703
   PubMed Web of Science ®Google Scholar
• KavanaughAMeasePJGomez-ReinoJJTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorAnn Rheum Dis20147361020102624595547
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABPSUMMIT 1 Study GroupEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet2013382989478078923769296
   PubMed Web of Science ®Google Scholar
• CoatesLCGossecLRamiroSNew GRAPPA and EULAR recommendations for the management of psoriatic arthritisRheumatology (Oxford)20175681251125328077693
   PubMed Web of Science ®Google Scholar
• GossecLCoatesLCDe WitMManagement of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendationsNat Rev Rheumatol2016121274375027829672
   PubMed Web of Science ®Google Scholar
• LoriesRJDe VlamKIs psoriatic arthritis a result of abnormalities in acquired or innate immunity?Curr Rheumatol Rep201214437538222527951
   PubMed Web of Science ®Google Scholar
• BenhamHNorrisPGoodallJTh17 and Th22 cells in psoriatic arthritis and psoriasisArthritis Res Ther2013155R13624286492
   PubMed Web of Science ®Google Scholar
• DhawaleRMorelandLWT-cell co-stimulationHochbergMCSilmanAJSmolenJSWeinblattMEWeismanMHRheumatology5th edPhiladelphia, PAElsevier2011557562
   Google Scholar
• MeasePJGottliebABvan der HeijdeDEfficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisAnn Rheum Dis20177691550155828473423
   PubMed Web of Science ®Google Scholar
• RitchlinCTColbertRAGladmanDDPsoriatic arthritisN Engl J Med20173761095797028273019
   PubMed Web of Science ®Google Scholar
• MenonBGullickNJWalterGJInterleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progressionArthritis Rheumatol20146651272128124470327
   PubMed Web of Science ®Google Scholar
• RaychaudhuriSKSaxenaARaychaudhuriSPRole of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritisClin Rheumatol20153461019102325939522
   PubMed Web of Science ®Google Scholar
• RaychaudhuriSPRaychaudhuriSKGenoveseMCIL-17 receptor and its functional significance in psoriatic arthritisMol Cell Biochem20123591–241942921894442
   PubMed Web of Science ®Google Scholar
• MeasePJMcInnesIBKirkhamBFUTURE 1 Study GroupSecukinumab inhibition of interleukin-17A in patients with psoriatic arthritisN Engl J Med2015373141329133926422723
   PubMed Web of Science ®Google Scholar
• MeasePJVan Der HeijdeDRitchlinCTSPIRIT-P1 Study GroupIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Ann Rheum Dis2017761798727553214
   PubMed Web of Science ®Google Scholar
• RitchlinCRahmanPKavanaughAPSUMMIT 2 Study GroupEfficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialAnn Rheum Dis201473699099924482301
   PubMed Web of Science ®Google Scholar
• GoedkoopAYKraanMCTeunissenMBMEarly effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritisAnn Rheum Dis200463776977315194570
   PubMed Web of Science ®Google Scholar
• BoutetMANervianiAGallo AfflittoGPitzalisCRole of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and jointsInt J Mol Sci2018192E53029425183
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDKeystoneECAlefacept in Psoriatic Arthritis Study GroupAlefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled studyArthritis Rheum20065451638164516646026
   PubMed Web of Science ®Google Scholar
• IannoneFLapadulaGThe inhibitor of costimulation of T cells: abataceptJ Rheumatol Suppl20128910010222751606
   PubMedGoogle Scholar
• KremerJMWesthovensRLeonMTreatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4IgN Engl J Med2003349201907191514614165
   PubMed Web of Science ®Google Scholar
• GenoveseMCBeckerJ-CSchiffMAbatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med2005353111114112316162882
   PubMed Web of Science ®Google Scholar
• SzentpeteryAHeffernanEGogartyMAbatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritisArthritis Res Ther201719115828679449
   PubMed Web of Science ®Google Scholar
• BathonJRoblesMXimenesACSustained disease remission and inhibition of radiographic progression in methotrexate-naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomesAnn Rheum Dis201170111949195621821865
   PubMed Web of Science ®Google Scholar
• RupertoNLovellDJQuartierPPaediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study GroupAbatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trialLancet2008372963638339118632147
   PubMed Web of Science ®Google Scholar
• KremerJMGenantHKMorelandLWEffects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trialAnn Intern Med20061441286587616785475
   PubMed Web of Science ®Google Scholar
• KeystoneECKremerJMRussellAAbatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE studyAnn Rheum Dis201271685786122302417
   PubMed Web of Science ®Google Scholar
• GenoveseMCCovarrubiasALeonGSubcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis Rheum201163102854286421618201
   PubMed Web of Science ®Google Scholar
• WeinblattMCombeBCovucciAArandaRBeckerJCKeystoneESafety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled studyArthritis Rheum20065492807281616947384
   PubMed Web of Science ®Google Scholar
• MeasePGenoveseMCGladsteinGAbatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialArthritis Rheum201163493994821128258
   PubMed Web of Science ®Google Scholar
• LekpaFKFarrenqVCanouï-PoitrineFLack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibitionJoint Bone Spine2012791475021497538
   PubMed Web of Science ®Google Scholar
• AbramsJRLebwohlMGGuzzoCACTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgarisJ Clin Invest199910391243125210225967
   PubMed Web of Science ®Google Scholar
• WeinblattMEMorelandLWWesthovensRSafety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial programJ Rheumatol201340678779723588946
   PubMed Web of Science ®Google Scholar
• AltenRKaineJKeystoneENashPDelaetIGenoveseMCLong-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatmentArthritis Rheumatol20146681987199724782324
   PubMed Web of Science ®Google Scholar
• KumarMRayLVemuriSSimonTAPregnancy outcomes following exposure to abatacept during pregnancySemin Arthritis Rheum201545335135626210783
   PubMed Web of Science ®Google Scholar
• NashPNayiagerSGenoveseMCImmunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label studyArthritis Care Res2013655718728
   PubMed Web of Science ®Google Scholar
• SmolenJSSchölsMBraunJTreating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task forceAnn Rheum Dis201777131728684559
   PubMed Web of Science ®Google Scholar
• FelsonDTAndersonJJBoersMAmerican College of Rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis Rheum19953867277357779114
   PubMed Web of Science ®Google Scholar
• UngprasertPThongprayoonCDavisJMIndirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysisSemin Arthritis Rheum201645442843826610638
   PubMed Web of Science ®Google Scholar
• KawalecPHolkoPMoćkoPPilcAComparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysisRheumatol Int201738218920129285605
   PubMed Web of Science ®Google Scholar
• MeasePJGottliebABBermanAThe efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritisArthritis Rheumatol20166892163217327059799
   PubMed Web of Science ®Google Scholar
• JungNHellmannMHoheiselRAn open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)Clin Rheumatol201029101169117320532937
   PubMed Web of Science ®Google Scholar
• Jimenez-BojEStammTASadlonovaMRituximab in psoriatic arthritis: an exploratory evaluationAnn Rheum Dis201271111868187122833373
   PubMed Web of Science ®Google Scholar
• MeasePHallSFitzGeraldOTofacitinib or adalimumab versus placebo for psoriatic arthritisN Engl J Med2017377161537155029045212
   PubMed Web of Science ®Google Scholar